Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate therapies for solid tumors, is pleased to announce its debut public ...

BioDuro has opened a new lab in Shanghai, China for highly potent compound synthesis at the hundred-gram scale.

MGC026, which is a TOP1i-based ADC, is undergoing a phase 1 dose-escalation study in patients with advanced solid tumors. The ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate ...

TwoStep Therapeutics, a biotechnology company developing innovative, first-in-class, multispecific targeted peptide conjugate ... of its lead tumor-targeted drug conjugate program, along with ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Here, we developed Fc-binder electrophilic peptides for the delivery of therapeutic drugs to native immunoglobulins (IgG). More than just another tool to engineer antibody-drug-conjugates ...